SEC Form 4 · accession 0000904454-16-001285
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kim P. Kamdar
Director · 10% Owner
Period of report
Jun 21, 2016
Accepted (ET)
Jun 23, 2016 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.13 | Jun 21, 2016 | A | 12,450 | A | Jun 21, 2017 | Jun 21, 2026 | Common Stock | 12,450 | 12,450 | D |
| Stock Option (Right to Buy) | $1.13 | Jun 21, 2016 | A | 16,393 | A | Jun 21, 2016 | Jun 21, 2026 | Common Stock | 16,393 | 16,393 | D |
| Stock Option (Right to Buy)F1 | $1.13 | Jun 21, 2016 | A | 24,590 | A | — | Jun 21, 2026 | Common Stock | 24,590 | 24,590 | D |
Explanation of responses
- F1The option vests as follows: 8,197 shares on 6/30/2016, 8,197 shares on 9/30/16 and 8,196 shares on 12/31/2017.